Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4049/jimmunol.1400063 http://scihub22266oqcxt.onion/10.4049/jimmunol.1400063 C4106678!4106678!24890727     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Immunol 2014 ; 193 (1): 48-55 Nephropedia Template TP {{tp|p=24890727|t=2014. Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts1 |pdf=|usr=}}{{24890727}} gab.com Text Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts1 JO: J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=24890727 #FOAvip Immunogenicity remains the ?Achilles? heel? of protein-based therapeutics. Anti-drug antibodies produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding class of agent. Here we report that monotherapy of mice with tofacitinib (the Janus kinase inhibitor) quells antibody responses to an immunotoxin derived from the bacterial protein, Pseudomonas exotoxin A, as well as to the model antigen, keyhole limpet hemocyanin. Thousandfold reductions in IgG1 titers to both antigens were observed 21 days post-immunization. In fact, suppression was evident for all IgG isotypes and IgM. A reduction in IgG3 production was also noted with a thymus-independent type II antigen. Mechanistic investigations revealed that tofacitinib treatment led to reduced numbers of CD127+ pro-B cells. Furthermore, we observed fewer germinal center B cells and the impaired formation of germinal centers of mice treated with tofacitinib. Since normal immunoglobulin levels were still present during the tofacitinib treatment, this agent specifically reduced anti-drug antibodies, thus preserving the potential efficacy of biological therapeutics, including those that are used as cancer therapeutics. Twit Text FOAVip Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts1 ????J Immunol http://www.kidney.de/pget.php?&tw=1&pmid=24890727 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24890727 #FOAvip English Wikipedia <ref>{{Cite pmid|24890727}}</ref> Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts1 #MMPMID24890727 Onda M; Ghoreschi K; Steward-Tharp S; Thomas C; O?Shea JJ; Pastan IH; FitzGerald DJ J Immunol 2014[Jul]; 193 (1): 48-55 PMID24890727show ga Immunogenicity remains the ?Achilles? heel? of protein-based therapeutics. Anti-drug antibodies produced in response to protein therapeutics can severely limit both the safety and efficacy of this expanding class of agent. Here we report that monotherapy of mice with tofacitinib (the Janus kinase inhibitor) quells antibody responses to an immunotoxin derived from the bacterial protein, Pseudomonas exotoxin A, as well as to the model antigen, keyhole limpet hemocyanin. Thousandfold reductions in IgG1 titers to both antigens were observed 21 days post-immunization. In fact, suppression was evident for all IgG isotypes and IgM. A reduction in IgG3 production was also noted with a thymus-independent type II antigen. Mechanistic investigations revealed that tofacitinib treatment led to reduced numbers of CD127+ pro-B cells. Furthermore, we observed fewer germinal center B cells and the impaired formation of germinal centers of mice treated with tofacitinib. Since normal immunoglobulin levels were still present during the tofacitinib treatment, this agent specifically reduced anti-drug antibodies, thus preserving the potential efficacy of biological therapeutics, including those that are used as cancer therapeutics. äTofacitinib Suppresses Antibody Responses to Protein Therapeutics in M(epmc).pdf DeepDyve Pubget Overpricing